TRDAEntrada Therapeutics, Inc.
The Read
3% following FDA catalysts, with mixed reactions to clinical data and earnings, often driven by positive updates on drug development and competitive landscape shifts.
The schedule
- Tue15Sep
Assessment of President Trump's administration policies regarding FDA oversight, clinical trial design flexibility, and biotech funding allocations.
- Thu8Oct
Crucial make-or-break clinical data for the higher dose cohort of the ENTR-601-44 Phase 1/2 study in DMD.
- Wed10Feb
Q3 financial print detailing the post-ELEVATE clinical strategy and end-of-year cash preservation efforts.
- Sun14Feb
Year-end financial results, setting the operational and clinical tone for fiscal 2027.
- Thu6May
First quarter 2027 results, focusing on early-stage preclinical asset progression or strategic M&A optionality.
Past
- Wed12Aug
Actual outcome: Bull
Entrada Therapeutics reported Q2 earnings that met EPS estimates and topped revenue expectations. The company also provided a concrete timeline for near-term clinical milestones, including data readouts for its ELEVATE-44-201 and ELEVATE-45-201 programs expected between late 2026 and early 2027. This combination of steady financial execution and clear visibility into upcoming pipeline catalysts reassured investors regarding the company's cash runway and strategic progress, keeping the stock above the $7.00 bull target.
Quarterly earnings report with extreme focus on capital allocation, given the severe cash burn profile against dwindling reserves.
- Mon20Jul
Actual outcome: Bull · $7.46 at outcome
Competitor regulatory updates in the Duchenne muscular dystrophy (DMD) space favorably altered the competitive landscape for Entrada. These developments highlighted the differentiation and potential advantages of Entrada's platform, driving a 17.7% rally as investors gained confidence in its relative valuation and pipeline prospects.
Expected readout or regulatory update from competitors in the heavily contested DMD space, which will heavily influence Entrada's relative platform valuation.
- Thu7May
Actual outcome: Mixed · $6.83 at outcome
Entrada Therapeutics reported topline results from Cohort 1 of its Phase 1/2 study for ENTR-601-44, highlighting favorable safety and early functional improvements in Duchenne muscular dystrophy patients. Despite the positive clinical updates, the trial data and a Q1 earnings miss initially triggered a sharp selloff. However, the stock ultimately stabilized and recovered to close completely flat by the outcome date, resulting in a mixed overall reaction.
Clinical milestone readout for ENTR-601 coupled with the high probability of a follow-on equity financing event.
- Thu7May
Actual outcome: Bear · $6.83 at outcome
Entrada Therapeutics experienced a brutal stock selloff, driving shares well below the bear floor, following the release of its Phase 1/2 ELEVATE-44-201 clinical trial data for Duchenne muscular dystrophy. Although the company reported favorable safety and early functional improvements alongside an in-line Q1 earnings report, the market reacted negatively to observations of lower plasma exposure in Cohort 1 participants.
Q1 2026 results and management’s commentary on cash runway and potential capital raises will frame dilution risk; reaffirmed runway into key 2027 data with no near-term financing could support shares around $14.00, while a pulled-forward equity raise or shorter runway could drag the stock toward $14.00.
- Wed6May
Actual outcome: Bull · $7.32 at outcome
Entrada Therapeutics announced topline results from Cohort 1 of its Phase 1/2 ELEVATE-44-201 study for Duchenne muscular dystrophy. Despite reporting favorable safety and early functional improvement, the clinical data underwhelmed investors and sparked a brutal selloff, which was further
Expected timeline for TRDA to file a new IND or provide an expanded dataset demonstrating the broader utility of its EEV platform.
- Wed15Apr
Actual outcome: Bear · $12.72 at outcome
Ahead of the event, Entrada reached a 52-week high following an Oppenheimer upgrade and a price target increase to $23.00. However, shares subsequently reversed course and plummeted to $6.84 by the run date, falling well below the $8.50 bear floor. This severe decline indicates that the highly anticipated ENTR-601 clinical data failed to meet market expectations, undermining confidence in the EEV platform and triggering a decisively bearish sell-off.
Initial clinical data from ENTR-601 in Duchenne muscular dystrophy could re-rate Entrada as a leading DMD genetic medicine player, with strong efficacy and safety potentially driving the stock toward $18.00, while inconclusive or negative data could undermine the EEV platform and push shares down toward $18.00.
- Thu26Feb
Actual outcome: Bull · $12.50 at outcome
Entrada met EPS estimates and provided positive clinical updates, including an Independent Data Monitoring Committee recommendation to increase the dosage in the ELEVATE-44-201 study. Management's confirmation of multiple data catalysts for 2026 and a stable cash runway addressed previous concerns regarding high burn rates, supporting the stock's climb to $12.70 by the run date.
The focus will be on the high cash burn rate from Q3 2025 and the resulting short cash runway. Management commentary or lack thereof regarding immediate financing/milestone payments will drive the price.
